These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

875 related articles for article (PubMed ID: 10395885)

  • 1. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Winters MA; Baxter JD; Mayers DL; Wentworth DN; Hoover ML; Neaton JD; Merigan TC
    Antivir Ther; 2000 Mar; 5(1):57-63. PubMed ID: 10846594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse transcriptase fidelity and HIV-1 variation.
    Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
    Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
    [No Abstract]   [Full Text] [Related]  

  • 10. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals.
    Torti C; Bono L; Gargiulo F; Uccelli MC; Quiros-Roldan E; Patroni A; Paraninfo G; Tirelli V; Manca N; De Francesco MA; Perandin F; Carosi G
    Clin Microbiol Infect; 2004 Sep; 10(9):826-30. PubMed ID: 15355414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
    Soriano V
    Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance in non-subtype B HIV-1.
    Kantor R; Katzenstein D
    J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral drug resistance among HIV-1 infected children failing treatment.
    Mullen J; Leech S; O'Shea S; Chrystie IL; Du Mont G; Ball C; Sharland M; Cottam F; Zuckerman M; Rice P; Easterbrook P
    J Med Virol; 2002 Nov; 68(3):299-304. PubMed ID: 12226814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
    Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
    Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia).
    Pérez-Alvarez L; Cuevas MT; Villahermosa ML; Pedreira JD; Manjón N; Herrero I; López-Calvo S; Delgado E; de Parga EV; Medrano L; Thomson MM; Taboada JA; Nájera R;
    J Hum Virol; 2001; 4(1):35-8. PubMed ID: 11213931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 44.